Clinical Trial

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and durvalumab may work better in treating patients with high-risk liver cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-01-04; most recent amendment 2026-07-16.
Status change: Recruiting → Active, Not Recruiting 2025-08-27
Status change: Not Yet Recruiting → Recruiting 2023-08-15
Trial Details
NCT Number NCT05194293
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Enrollment 4 participants
Start Date 2023-07-01
Primary Completion 2025-12-05 (estimated)
Study Completion 2028-12-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-20